Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 12

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 12
---
 any change in practice to Shareholders’ ownership rights.

Uncertificated AstraZeneca Shares held through CREST and traded on the London Stock Exchange (other than Affiliate Shares)

For the AstraZeneca Shares to be listed on the NYSE, AstraZeneca Shares must be eligible for deposit and clearing through DTC, which means that they cannot be held directly via CREST. Legal title to the AstraZeneca Shares traded on the London Stock Exchange (other than Affiliate Shares) will instead be transferred to the DTC Nominee at the Effective Time, and AstraZeneca DIs will be issued on a one for one basis to the relevant CREST accounts through which the relevant interests in AstraZeneca Shares were held immediately prior to the Effective Time by or for the account of the relevant uncertificated holder.

As a technical matter, following the implementation of the Settlement System Migration, Shareholders wishing to trade their AstraZeneca Shares on the London Stock Exchange will transfer and settle their interests in AstraZeneca Shares through CREST in the form of AstraZeneca DIs. AstraZeneca DIs will be automatically applied to the account through which such Shareholders currently hold their entitlement to AstraZeneca Shares at the Effective Time without any further action required by the relevant Shareholder. In practice, such Shareholders will continue to have substantially the same trading and settlement experience in the UK as they have today.

For the avoidance of doubt, existing CSN Participants will continue to hold their interests in AstraZeneca Shares (settled in the form of AstraZeneca DIs following the Effective Time) through the CSN Facility, with the CSN Nominee holding such interests as nominee for and on behalf of the relevant underlying holders on the CSN Terms and Conditions annexed to this document, which will differ from the terms and conditions in place immediately prior to the Effective Time insofar as is required to reflect the Settlement System Migration.

Following the Effective Time, it is anticipated that awards under the AstraZeneca Share Plans that, under current arrangements, would be settled with AstraZeneca Shares traded on the London Stock Exchange will instead be settled with an equivalent number of AstraZeneca DIs, and share awards that, under current arrangements, would be settled with AstraZeneca ADSs will instead be settled with the number of AstraZeneca Shares those AstraZeneca ADSs represent. The changes to settlement and dealings described above will apply equally to AstraZen